News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AlphaCore Pharma Initiates ACP-501 (rhLCAT) Clinical Trial in Patients With Coronary Artery Disease



3/30/2012 11:06:47 AM

ANN ARBOR, Mich.--(BUSINESS WIRE)--AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced the initiation of a Phase 1 study of ACP-501 in patients with stable coronary arterial disease. The study is designed to assess the safety, tolerability, pharmacokinetics and lipid effects of ACP-501. The trial will be conducted by the National Institute of Health (NIH) and Robert D. Shamburek, MD, will serve as the principal investigator of the study.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES